JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 82.2%

Neg 0% Neu 0% Pos 82.2%

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target from $34 to $45.